HCA Healthcare EVP and COO Jon Foster sells $15.9M in stock

HCA Healthcare's Executive Vice President and Chief Operating Officer, Jon M. Foster, divested approximately $15.9 million worth of company stock in early November 2026. Foster sold 31,713 shares on November 4 and 6, at prices between $491.9817 and $514.0698 per share. Currently trading at $494.99, or a 4.6% increase over the past week, HCA's stock was assessed by InvestingPro as potentially undervalued.

On the same day as the initial sale, Foster acquired 35,880 shares through the exercise of stock appreciation rights, valued at about $5.21 million. These rights, which had vested in four annual installments starting January 29, 2021, were purchased at an exercise price of $145.24 per share. Additionally, Foster sold 20,309 shares on November 4 to satisfy tax withholding requirements, amounting to $10.37 million.

He also transferred 16,142 shares from a trust to direct ownership, changing the form of beneficial ownership without altering the total number of shares he owned. HCA Healthcare, a $106 billion healthcare provider, was rated with a strong financial health score by InvestingPro, which provides 10 exclusive ProTips for the company.

In recent earnings, HCA reported strong third-quarter 2026 results, with adjusted earnings per share of $7.22, surpassing analysts' expectations of $6.65. Revenue also exceeded estimates at $19.85 billion compared to the forecasted $19.33 billion. However, the company noted some challenges, such as exchange-related volume losses and a softer earnings outlook for 2027, which may have dampened investor enthusiasm.

Despite these concerns, HCA received a price target adjustment from BofA Securities, raising it from $450 to $500 and maintaining a Neutral rating due to the company's solid performance and potential benefits from supplemental Medicaid programs. HCA also saw growth in same-facility adjusted admissions and emergency room visits, indicating sustained demand across its hospital network.

However, the rise in uninsured volume led to a $400 million decrease in adjusted EBITDA. HCA management indicated that 2027 earnings should be similar to 2026.